FXCM Pro Announces Liquidity Bridging Partnership With Tools for Brokers
5.9.2023 11:00:00 EEST | Business Wire | Press release
FXCM Pro, the institutional arm of FXCM, a leading international provider of online foreign exchange trading, CFD trading and related services has announced a liquidity bridging partnership with Tools for Brokers (TFB), an international technology provider for retail brokers, prop trading companies, and hedge funds.
FXCM Pro will be streaming its institutional liquidity directly to TFB clients, enabling them to connect pricing and trading to their MT4 and MT5 platforms using TFB’s FIX API server. With this new partnership, FXCM Pro’s clients will benefit from having an additional option when selecting a technology/bridge provider.
TFB’s Trade Processor bridge works with the MT4 and MT5, cTrader, Match-Trader, and other platforms and supports third-party integrations via external FIX API. Additionally, it provides brokers with data analysis and enhanced risk management, all through a simple, user-friendly interface.
Mario Sanchez, Managing Director and Global Head of FXCM Pro Sales, commented: “At FXCM Pro, we are committed to providing our clients with the technology they need to succeed, and this is demonstrated in our partnership with Tools for Brokers. This collaboration gives our clients additional choice when it comes to selecting a bridging provider and by selecting TFB, they will benefit from fast execution, automation and improved market access.”
Alexey Kutsenko, CEO at Tools for Brokers, said, “We are excited to partner with FXCM Pro. Under the partnership, FXCM Pro’s clients will benefit from advanced and fast execution without compromising quality or security. Combining our experience and expertise will create a strong platform for many brokerages and hedge funds, allowing them to scale faster and more sustainably.”
FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. Its relationships with tier 1 banks and non-bank liquidity providers, prime broker relationships and technology vendors provide clients with best-in-class market access.
Tools for Brokers (TFB) is an international technology provider for retail brokers, prop trading companies, and hedge funds operating on multiple platforms, including MetaTrader, Match-Trader, and cTrader. It offers an ecosystem of solutions centred around the flagship Trade Processor liquidity bridge, supported by data management and reporting, money management, and a single web-user interface for individual solutions’ management.
For more information on FXCM, please visit http://www.fxcm.com/
For more information on TFB, please visit https://t4b.com/
###
Disclaimers:
This communication is intended for institutional and professional clients only.
About FXCM:
FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards, and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one-click order execution and trading from real-time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime.
About Tools for Brokers:
Tools for Brokers (TFB) is a multiplatform technology provider for retail brokers, prop trading companies, and hedge funds with solutions operating on MetaTrader, Match-Trader, and cTrader. The ecosystem of products centers around the Trade Processor liquidity bridge, enhanced with data management and reporting functionality, TFB PAMM for money management, and the TFB Toolbox — a single web-user interface for individual custom solutions’ management. The flagship multiplatform liquidity bridge solution — Trade Processor — supports a pool of liquidity providers, helps clients manage risks, collects data, and automates the most critical processes all through a single console.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905624094/en/
Contact information
FXCM Media contact:
Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com
Tools for Brokers contact:
Yulia Ogorodnikova
y.ogorodnikova@t4b.com
Tel: +447503599088
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu
Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release
Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom